NewAmsterdam Pharma Company NV (NASDAQ: NAMS)’s stock price has plunge by 1.08relation to previous closing price of 18.45. Nevertheless, the company has seen a 3.84% surge in its stock price over the last five trading sessions. globenewswire.com reported 2025-06-09 that — Pre-specified analyses show that obicetrapib treatment leads to statistically significant and clinically meaningful reductions in the primary outcome measure of Alzheimer’s disease biomarker in both the full ITT population (p
Is It Worth Investing in NewAmsterdam Pharma Company NV (NASDAQ: NAMS) Right Now?
The 36-month beta value for NAMS is at -0.02. Analysts have varying views on the stock, with 8 analysts rating it as a “buy,” 4 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for NAMS is 62.20M, and currently, shorts hold a 11.21% of that float. The average trading volume for NAMS on June 27, 2025 was 888.15K shares.
NAMS’s Market Performance
The stock of NewAmsterdam Pharma Company NV (NAMS) has seen a 3.84% increase in the past week, with a 7.74% rise in the past month, and a -16.78% fall in the past quarter. The volatility ratio for the week is 5.37%, and the volatility levels for the past 30 days are at 6.59% for NAMS. The simple moving average for the last 20 days is -3.10% for NAMS stock, with a simple moving average of -7.78% for the last 200 days.
Analysts’ Opinion of NAMS
Many brokerage firms have already submitted their reports for NAMS stocks, with Citigroup repeating the rating for NAMS by listing it as a “Buy.” The predicted price for NAMS in the upcoming period, according to Citigroup is $42 based on the research report published on June 17, 2025 of the current year 2025.
Stifel, on the other hand, stated in their research note that they expect to see NAMS reach a price target of $44. The rating they have provided for NAMS stocks is “Buy” according to the report published on June 10th, 2025.
Cantor Fitzgerald gave a rating of “Overweight” to NAMS, setting the target price at $42 in the report published on June 04th of the current year.
NAMS Trading at -0.06% from the 50-Day Moving Average
After a stumble in the market that brought NAMS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -31.66% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at NAMS starting from Topper James N, who purchase 2,520 shares at the price of $18.43 back on Jun 24 ’25. After this action, Topper James N now owns 3,024,873 shares of NewAmsterdam Pharma Company NV, valued at $46,454 using the latest closing price.
Topper James N, the Director of NewAmsterdam Pharma Company NV, purchase 1,260 shares at $18.26 during a trade that took place back on Jun 25 ’25, which means that Topper James N is holding 3,026,133 shares at $23,012 based on the most recent closing price.
Stock Fundamentals for NAMS
Current profitability levels for the company are sitting at:
- -4.02 for the present operating margin
- 1.0 for the gross margin
The net margin for NewAmsterdam Pharma Company NV stands at -3.97. The total capital return value is set at -0.24. Equity return is now at value -31.51, with -28.67 for asset returns.
Based on NewAmsterdam Pharma Company NV (NAMS), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -351.54.
Currently, EBITDA for the company is -241.49 million with net debt to EBITDA at 2.92. When we switch over and look at the enterprise to sales, we see a ratio of 28.7. The liquidity ratio also appears to be rather interesting for investors as it stands at 19.98.
Conclusion
In conclusion, NewAmsterdam Pharma Company NV (NAMS) has had a mixed performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
